Orion Oyj (FRA:OFK)

Germany flag Germany · Delayed Price · Currency is EUR
69.00
-1.50 (-2.13%)
At close: Jan 30, 2026
33.72%
Market Cap9.79B +53.1%
Revenue (ttm)1.63B +14.0%
Net Income313.20M -5.6%
EPS2.23 -5.6%
Shares Outn/a
PE Ratio31.24
Forward PE19.01
Dividend1.64 (2.38%)
Ex-Dividend DateOct 15, 2025
Volumen/a
Average Volume11
Open68.80
Previous Close70.50
Day's Range68.80 - 69.00
52-Week Range47.60 - 73.05
Betan/a
RSI55.50
Earnings DateFeb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art... [Read more]

Industry Pharmaceutical Preparations
Founded 1917
Employees 4,030
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol OFK
Full Company Profile

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial Statements